Bassig Bryan A, Shu Xiao-Ou, Koh Woon-Puay, Gao Yu-Tang, Purdue Mark P, Butler Lesley M, Adams-Haduch Jennifer, Xiang Yong-Bing, Kemp Troy J, Wang Renwei, Pinto Ligia A, Zheng Tongzhang, Ji Bu-Tian, Hosgood H Dean, Hu Wei, Yang Gong, Zhang Heping, Chow Wong-Ho, Kim Christopher, Seow Wei Jie, Zheng Wei, Yuan Jian-Min, Lan Qing, Rothman Nathaniel
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.
Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Int J Cancer. 2015 Dec 1;137(11):2688-95. doi: 10.1002/ijc.29637. Epub 2015 Jun 26.
Prospective studies conducted in Western populations have suggested that alterations in soluble CD27 (sCD27) and soluble CD30 (sCD30), two markers indicative of B-cell activation, are associated with risk of non-Hodgkin lymphoma (NHL). Given that the characteristics of NHL in East Asia differ from the West and mechanistic commonalities between these populations with respect to the role of intermediate endpoint biomarkers in lymphomagenesis have not been explored, we conducted a pooled nested case-control study from three prospective studies of Chinese men and women including 218 NHL cases and 218 individually matched controls. Compared with the lowest quartile, ORs (95% CIs) for the second, third and fourth quartiles of sCD27 were 1.60 (0.83-3.09), 1.94 (0.98-3.83) and 4.45 (2.25-8.81), respectively (p(trend) = 0.000005). The corresponding ORs for sCD30 were 1.74 (0.85-3.58), 1.86 (0.94-3.67) and 5.15 (2.62-10.12; p(trend) = 0.0000002). These associations remained statistically significant in individuals diagnosed with NHL 10 or more years after blood draw. Notably, the magnitude of the associations with NHL risk was very similar to those in Western populations in previous studies. These findings of the similar association between sCD27 or sCD30 and NHL risk across different populations support an important underlying mechanism of B-cell activation in lymphomagenesis.
在西方人群中进行的前瞻性研究表明，可溶性CD27（sCD27）和可溶性CD30（sCD30）这两种B细胞活化标志物的改变与非霍奇金淋巴瘤（NHL）风险相关。鉴于东亚地区NHL的特征与西方不同，且尚未探讨这些人群在淋巴瘤发生过程中中间终点生物标志物作用方面的机制共性，我们对三项针对中国男性和女性的前瞻性研究进行了汇总巢式病例对照研究，包括218例NHL病例和218例个体匹配对照。与最低四分位数相比，sCD27第二、第三和第四四分位数的OR值（95%CI）分别为1.60（0.83 - 3.09）、1.94（0.98 - 3.83）和4.45（2.25 - 8.81）（p趋势 = 0.000005）。sCD30的相应OR值分别为1.74（0.85 - 3.58）、1.86（0.94 - 3.67）和5.15（2.62 - 10.12；p趋势 = 0.0000002）。在采血后10年或更长时间被诊断为NHL的个体中，这些关联在统计学上仍然显著。值得注意的是，与NHL风险的关联程度与先前研究中西方人群的关联程度非常相似。不同人群中sCD27或sCD30与NHL风险之间类似关联的这些发现支持了淋巴瘤发生过程中B细胞活化的重要潜在机制。
